Selected by a specialist research team following comparisons across multiple sources, adding to Huanzhang’s supply record within the Shanghai Pharmaceuticals system.
Huanzhang has received a follow-up purchase of Antrodia cinnamomea raw material from a clinical pharmacology research team at Jiangsu Provincial Hospital of Chinese Medicine. Drawing on approximately two years of multi-source sample analysis, the team purchased Huanzhang’s material for composition comparison and, after the initial analysis, placed a follow-up order for continued research.
According to Huanzhang’s discussions with the research team, the team has studied Antrodia cinnamomea for approximately two years and purchased raw materials from multiple sources for composition analysis. Among the samples previously analyzed, material supplied by a leading, long-established Chinese traditional medicine company had shown the strongest composition indicators and served as an important reference for subsequent selection.
The team then purchased Huanzhang material for analysis against this existing comparison base. According to feedback provided by the team to Huanzhang, Huanzhang’s sample exceeded the previously best-performing pharmaceutical-company sample on the principal constituent-content indicators included in this comparison. Following this result, the team placed a follow-up order for Huanzhang’s raw material to support further research.
The progression from multi-source comparisons and an established reference sample to selection and follow-up procurement provides a concrete research-use example of Huanzhang’s material composition strengths. It also demonstrates how the company’s cultivation and composition management capabilities can meet research material requirements.
For industrial customers, Huanzhang’s Antrodia material previously completed quality review within the Shanghai Pharmaceuticals system and entered the Antrodia raw-material supply chain of Chongqing Shangyao Huiyuan Qinglong Pharmaceutical Co., Ltd., a company within that system. Selection by a specialist pharmacology research team adds a further example of actual use, alongside Huanzhang’s supply record with a major pharmaceutical group.
The research team is currently investigating Antrodia cinnamomea in a depression-related research area. It plans to continue animal experiments and evaluate potential clinical research arrangements in light of the results. Further research-material requirements will be determined as the study plan develops.